Page 33 - Read Online

receptors (HERs) in gastric carcinomas: HER2 and HER3 are Tanaka M, Katano M. Increased nuclear factor-kB activation
predictors of poor outcome. J Clin Oncol 2011;29:3030-6. in human colorectal carcinoma and its correlation with tumor
19. Fakih M. Targeting mechanisms of resistance to anti-EGF progression. Anticancer Res 2004;24:675-81.
receptor therapy in KRAS wild-type colorectal cancer: the path 38. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal
to more personalized medicine. Future Oncol 2013;9:551-60. antiinfl ammatory drugs inhibit the proliferation of colon
20. Bronte G, Terrasi M, Rizzo S, Sivestris N, Ficorella C, adenocarcinoma cells: effects on cell cycle and apoptosis.
Cajozzo M, Di Gaudio F, Gulotta G, Siragusa S, Gebbia N, Exp Cell Res 1996;222:179-88.
Russo A. EGFR genomic alterations in cancer: prognostic and 39. Algra AM, Rothwell PM. Effects of regular aspirin on
predictive values. Front Biosci (Elite Ed) 2011;3:879-87. long-term cancer incidence and metastasis: a systematic
21. Engelman JA, Luo J, Cantley LC. The evolution of comparison of evidence from observational studies versus
phosphatidylinositol 3-kinases as regulators of growth and randomised trials. Lancet Oncol 2012;13:518-27.
metabolism. Nat Rev Genet 2006;7:606-19. 40. Flossmann E, Rothwell PM. Effect of aspirin on long-term
22. Silvestris N, Tommasi S, Petriella D, Santini D, Fistola E, risk of colorectal cancer: consistent evidence from randomised
Russo A, Numico G, Tonini G, Maiello E, Colucci G. The and observational studies. Lancet 2007;369:1603-13.
dark side of the moon: the PI3K/PTEN/AKT pathway in 41. Zhang Y. Epidemiology of esophageal cancer. World J
colorectal carcinoma. Oncology 2009;77 Suppl 1:69-74. Gastroenterol 2013;19:5598-606.
23. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular 42. Homs MY, v d Gaast A, Siersema PD, Steyerberg EW,
pathways and new therapeutic targets. Semin Liver Dis Kuipers EJ. Chemotherapy for metastatic carcinoma of the
2005;25:212-25. esophagus and gastro-esophageal junction. Cochrane Database
24. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for Syst Rev 2006; CD004063.
hepatocellular carcinoma. Oncogene 2006;25:3866-84. 43. Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K,
25. Kolch W. Meaningful relationships: the regulation of Szeto L, Vokes EE. Phase II trial of oxaliplatin, leucovorin
the Ras/Raf/MEK/ERK pathway by protein interactions. and fl uorouracil in patients with advanced carcinoma of the
Biochem J 2000;351(Pt 2):289-305. esophagus. Ann Oncol 2005;16:1320-5.
26. Harden TK, Sondek J. Regulation of phospholipase C 44. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med
isozymes by ras superfamily GTPases. Annu Rev Pharmacol 2003;349:2241-52.
Toxicol 2006;46:355-79. 45. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G,
27. To MD, Perez-Losada J, Mao JH, Balmain A. Crosstalk Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V,
between Pten and Ras signaling pathways in tumor Park JO, Sawaki A, Celik I, Gotte H, Melezinkova H,
development. Cell Cycle 2005;4:1185-8. Moehler M. Capecitabine and cisplatin with or without
28. Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, cetuximab for patients with previously untreated advanced
Haller DG, Benedetti J, Francini G, Shepherd LE, Francois gastric cancer (EXPAND): a randomised, open-label phase 3
trial. Lancet Oncol 2013;14:490-9.
Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP,
Goldberg RM. Pooled analysis of fl uorouracil-based adjuvant 46. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF,
therapy for stage II and III colon cancer: who benefi ts and by Okines C, Wotherspoon A, Saffery C, Middleton G,
how much? J Clin Oncol 2004;22:1797-806. Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D,
29. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y.
Pathol 2011;6:479-507. Epirubicin, oxaliplatin, and capecitabine with or without
30. Gupta A, Verma A, Mishra AK, Wadhwa G, Sharma SK, panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): a randomised, open-label
Jain CK. The Wnt pathway: emerging anticancer phase 3 trial. Lancet Oncol 2013;14:481-9.
strategies. Recent Pat Endocr Metab Immune Drug Discov 47. Ling Y, Chen J, Tao M, Chu X, Zhang X. A pilot study of
2013;7:138-47. nimotuzumab combined with cisplatin and 5-FU in patients
31. Martensson A, Oberg A, Jung A, Cederquist K, Stenling R, with advanced esophageal squamous cell carcinoma. J Thorac
Palmqvist R. Beta-catenin expression in relation to genetic Dis 2012;4:58-62.
instability and prognosis in colorectal cancer. Oncol Rep 48. Shah MA, Ramanathan RK, Ilson DH, Levnor A,
2007;17:447-52. D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L,
32. Wanitsuwan W, Kanngurn S, Boonpipattanapong T, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II
Sangthong R, Sangkhathat S. Overall expression of study of irinotecan, cisplatin, and bevacizumab in patients
beta-catenin outperforms its nuclear accumulation in predicting with metastatic gastric or gastroesophageal junction
outcomes of colorectal cancers. World J Gastroenterol adenocarcinoma. J Clin Oncol 2006;24:5201-6.
2008;14:6052-9.
49. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E,
33. Elzagheid A, Buhmeida A, Korkeila E, Collan Y, Syrjanen K, Capanu M, Kelsen DP. Phase II study of modifi ed docetaxel,
Pyrhonen S. Nuclear beta-catenin expression as a prognostic cisplatin, and fl uorouracil with bevacizumab in patients with
factor in advanced colorectal carcinoma. World J Gastroenterol metastatic gastroesophageal adenocarcinoma. J Clin Oncol
2008;14:3866-71. 2011;29:868-74.
34. Okayama H, Schetter AJ, Harris CC. MicroRNAs and 50. Kamangar F, Dores GM, Anderson WF. Patterns of
infl ammation in the pathogenesis and progression of colon cancer incidence, mortality, and prevalence across fi ve
cancer. Dig Dis 2012;30 Suppl 2:9-15. continents: defi ning priorities to reduce cancer disparities
35. Hagemann T, Balkwill F, Lawrence T. Infl ammation and in different geographic regions of the world. J Clin Oncol
cancer: a double-edged sword. Cancer Cell 2007;12:300-1. 2006;24:2137-50.
36. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, 51. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC,
Kagnoff MF, Karin M. IKKbeta links infl ammation and Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
tumorigenesis in a mouse model of colitis-associated cancer. Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK.
Cell 2004;118:285-96. Trastuzumab in combination with chemotherapy versus
37. Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, chemotherapy alone for treatment of HER2-positive advanced
Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦ 169